Mold Illness (CIRS): Symptoms, Testing & Treatment

Quick answer: Mold-related illness (CIRS — Chronic Inflammatory Response Syndrome) affects an estimated 24% of the population who carry HLA-DR gene variants that prevent normal mycotoxin clearance. Unlike typical allergic mold reactions, CIRS is a multi-system biotoxin illness driven by innate immune dysregulation — not IgE-mediated allergy. The correct testing protocol includes HLA-DR genotyping, Visual Contrast Sensitivity (VCS) testing, C4a, TGF-beta-1, MSH, and urine mycotoxin panels. The validated treatment protocol is the Shoemaker Protocol combined with binders (cholestyramine or GI Detox), mold-free environment, and targeted correction of the downstream hormonal and immunological disruptions.

What Mold Illness Actually Is — And What It Is Not

Most people think of mold illness as an allergic condition — sneezing, itchy eyes, nasal congestion triggered by mold spore inhalation. This is a real phenomenon (IgE-mediated mold allergy), but it is not what is meant by mold illness in the functional medicine context. Chronic Inflammatory Response Syndrome (CIRS) — also called biotoxin illness — is a fundamentally different condition driven by an inability to clear mycotoxins through normal biotransformation pathways.

CIRS was characterized by Dr. Ritchie Shoemaker, a Maryland physician who identified a pattern of multi-system illness in patients with water-damaged building (WDB) exposure that persisted long after the exposure ended. The mechanism: approximately 24% of the population carry HLA-DR immune response gene variants (identified through HLA typing) that produce insufficient antibody responses to mycotoxins. In these individuals, mycotoxins are not tagged for clearance, recirculate through enterohepatic cycling, and trigger persistent innate immune system activation via NLRP3 inflammasome and complement cascade pathways. The resulting inflammatory state — marked by elevated C4a, MMP-9, TGF-beta-1, and VEGF — produces a multi-system illness that conventional medicine frequently misdiagnoses as depression, fibromyalgia, chronic fatigue syndrome, or anxiety disorder.

This distinction matters enormously: if you test negative for mold allergy on standard skin prick testing, that does not rule out CIRS. CIRS is not an allergic condition. It is a biotoxin-driven inflammatory condition in genetically susceptible individuals. The appropriate testing is entirely different.

The Most Common Mycotoxins and Their Sources

Not all molds are equally problematic. The primary mycotoxins implicated in CIRS and chronic illness are produced by specific mold species that thrive in water-damaged buildings:

Ochratoxin A (OTA): Produced by Aspergillus and Penicillium species. OTA is nephrotoxic (kidney-damaging), immunosuppressive, and a potent mycotoxin in urine testing. Primary sources: water-damaged buildings, coffee, grapes and wine, dried fruits, and certain cereals. OTA has a half-life of approximately 35 days in humans and is highly fat-soluble, enabling bioaccumulation. It is among the most commonly detected mycotoxins in CIRS urine panels.

Trichothecenes (especially DON and T-2 toxin): Produced by Stachybotrys chartarum (the notorious “black mold”) and Fusarium species. Trichothecenes are among the most potent mycotoxins, inhibiting protein synthesis, damaging GI mucosa, and suppressing immune function. Stachybotrys requires very high water activity (>0.95) and is found in heavily water-damaged materials — flooring, drywall, ceiling tiles — rather than in food. Exposure is almost exclusively from severely water-damaged buildings.

Aflatoxins (B1, B2, G1, G2): Produced by Aspergillus flavus and A. parasiticus. Aflatoxin B1 is the most potent naturally occurring carcinogen known. Primary sources are food — peanuts, corn, tree nuts, cottonseed — rather than building mold. Aflatoxins are hepatotoxic and immunosuppressive. Aflatoxin B1 exposure is associated with hepatocellular carcinoma risk. Most common in warm, humid climates and improperly stored grains.

Gliotoxin: Produced by Aspergillus fumigatus. Gliotoxin is immunosuppressive (it induces apoptosis in T cells and macrophages) and is associated with invasive aspergillosis in immunocompromised individuals. In CIRS patients, elevated gliotoxin on urine testing suggests significant Aspergillus exposure.

Zearalenone: Produced by Fusarium species. Zearalenone is a mycoestrogen — it binds estrogen receptors and disrupts endocrine function. In women, elevated zearalenone is associated with precocious puberty, menstrual disruption, and infertility. It is found in corn, wheat, and barley and is relevant primarily as a food contaminant rather than a building mold.

Symptoms of CIRS: Why Mold Illness Is So Often Missed

CIRS produces symptoms across essentially every organ system, which is why it is so frequently misdiagnosed or attributed to psychiatric conditions. The Shoemaker symptom cluster includes 37 symptoms organized by system — the breadth of symptom presentation is itself a diagnostic clue. Common symptom clusters include:

Neurological/cognitive: Brain fog, memory impairment (especially short-term), difficulty concentrating, word-finding difficulty, executive function decline. The neuroinflammatory mechanism is well-characterized: TGF-beta-1 elevation and VEGF dysregulation impair blood-brain barrier integrity and reduce cerebral perfusion. Neuroimaging can show reduced gray matter volume in affected individuals.

Fatigue and pain: Profound, unrefreshing fatigue that does not improve with sleep, widespread muscle aching, joint pain (often migratory), ice pick headaches. Many CIRS patients meet criteria for fibromyalgia or chronic fatigue syndrome — but treatment for those conditions typically fails because the underlying biotoxin driver is not addressed.

Respiratory: Shortness of breath (not triggered by allergen exposure — it is persistent), air hunger, cough, sinus congestion. The respiratory symptoms in CIRS are driven by VEGF dysregulation causing pulmonary capillary leak, not by airway mast cell degranulation as in allergic disease.

Gastrointestinal: Abdominal pain, nausea, diarrhea, bloating. The GI symptoms relate to direct mycotoxin damage to the intestinal epithelium and associated intestinal permeability and microbiome disruption.

Hormonal and immune dysregulation: MSH (melanocyte-stimulating hormone) deficiency — one of the most consistent CIRS findings — leads to pituitary hormone dysregulation, chronic pain sensitization (MSH modulates endorphins), and dysregulated inflammatory responses. ADH/osmolality dysregulation produces excessive thirst and urination. Testosterone and DHEA suppression are common in CIRS-affected men and women alike.

Sensory: Light sensitivity, difficulty adapting to low-contrast visual environments (tested by VCS), tearing, red eyes, static shocks.

The Correct Testing Protocol for Mold Illness

Standard allergy testing (IgE-based skin prick or RAST) is not the appropriate test for CIRS. The validated CIRS testing protocol includes:

Visual Contrast Sensitivity (VCS) Test

The VCS test (available free at survivingmold.com) measures the ability to detect low-contrast visual patterns — a neurological function that is specifically impaired by biotoxin-driven neuroinflammation. Sensitivity for CIRS is approximately 92% — a positive VCS result in a symptomatic patient with exposure history is strong evidence for CIRS. The test is not diagnostic alone, but a negative VCS result makes CIRS much less likely. VCS can also be used to monitor treatment response.

HLA-DR Genotyping

HLA-DR typing identifies whether the patient carries susceptibility genotypes. Approximately 24% of the population carry haplotypes associated with impaired mycotoxin clearance (the most common: HLA-DR 4-3-53, 11-3-52B, 12-3-52B, and the “dreaded” 4-3-53 / 11-3-52B “multisusceptible” pattern). This test does not diagnose CIRS but identifies susceptibility and explains why some people in the same building become severely ill while others are unaffected.

Inflammatory Biomarker Panel

The Shoemaker panel measures the specific inflammatory mediators dysregulated in CIRS. Key biomarkers: C4a (complement split product — elevated in >90% of untreated CIRS; normal is typically below 2,830 ECHO U/mL), TGF-beta-1 (typically markedly elevated in CIRS, often >2,380 pg/mL), MSH (typically below 35 pg/mL in CIRS — deficiency drives many downstream symptoms), VEGF (elevated initially, then may fall with chronicity), MMP-9 (elevated — drives neuroinflammation and blood-brain barrier disruption), ADH/osmolality, and VIP (vasoactive intestinal polypeptide — used to monitor treatment).

Urine Mycotoxin Testing

Direct urine mycotoxin testing (available through RealTime Labs and Great Plains Laboratory) measures actual mycotoxin body burden. This test detects ochratoxin A, trichothecenes, aflatoxins, zearalenone, and gliotoxin in urine. Provocative testing (using glutathione or DMSA to mobilize mycotoxins before the urine collection) increases sensitivity but remains controversial. Urine mycotoxin testing is most useful for confirming exposure and identifying specific mycotoxins to guide treatment. Limitations: it reflects current body burden and recent exposure, not cumulative historical exposure.

ERMI Environmental Testing

Environment Relative Moldiness Index (ERMI) testing uses PCR-based DNA analysis of dust samples to quantify mold species concentration relative to a national database. An ERMI score above 2 is considered elevated. The HERTSMI-2 (a subset of 5 high-risk species from the ERMI panel) is sometimes used as a simplified version. Environmental testing is essential — treating the patient without identifying and remediating the exposure source produces no lasting benefit.

The CIRS Treatment Protocol

Step 1: Remove from Exposure — Non-Negotiable

No treatment protocol works without eliminating ongoing exposure. This is the hardest and most important step. If the patient continues to live or work in a water-damaged building, all other interventions will fail. Environmental assessment (ERMI testing, professional inspection for visible mold and moisture intrusion) must precede treatment. For patients who cannot leave a problematic environment immediately, aggressive personal air filtration (HEPA + activated carbon units in bedroom and workspace) reduces but does not eliminate exposure.

Step 2: Mycotoxin Binding — Cholestyramine or GI Detox+

Mycotoxins undergo enterohepatic recirculation — they are excreted in bile, reabsorbed in the intestine, and recirculate indefinitely in susceptible individuals who cannot produce adequate antibody responses to tag them for elimination. Binding agents interrupt this cycle by capturing mycotoxins in the GI tract for fecal excretion. The Shoemaker Protocol uses cholestyramine (4g 4x/day, 30 minutes before meals and at bedtime) as the primary binder — cholestyramine has the strongest evidence base for CIRS specifically. Cholestyramine also binds many medications and fat-soluble nutrients, so timing separation from all other supplements and medications is critical.

Natural binder alternatives with evidence for mycotoxin binding include activated charcoal, bentonite clay, and modified citrus pectin. GI Detox+ (Bio-Botanical Research) combines bentonite clay, activated charcoal, apple pectin, and silica — this is a common non-prescription alternative. Saccharomyces boulardii specifically binds ochratoxin A and reduces its intestinal absorption. None of the natural alternatives match cholestyramine’s CIRS-specific evidence, but they are useful adjuncts or alternatives for patients who cannot tolerate cholestyramine (common side effects: constipation, bloating).

Step 3: Treat MARCoNS (If Present)

MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) is a deep nasal biofilm colonization found in approximately 80% of CIRS patients. MARCoNS produces exotoxins that further lower MSH (already suppressed by CIRS), perpetuating the inflammatory cycle. Testing requires a nasal swab with culture for coagulase-negative staph with antibiotic sensitivity. Treatment uses BEG nasal spray (Bactroban + EDTA + gentamicin) or EDTA + Ag spray (colloidal silver + EDTA) for 30 days. MARCoNS treatment must occur after binder therapy — starting before binders increases re-exposure risk.

Step 4: Correct the Downstream Hormonal and Immune Abnormalities

After binder therapy and MARCoNS treatment, several downstream CIRS abnormalities require targeted correction. These typically do not normalize on their own without specific intervention:

ACTH/cortisol axis: Many CIRS patients show low cortisol on stimulation testing secondary to hypothalamic-pituitary dysregulation. This requires evaluation and appropriate support — HPA axis restoration protocol with adaptogens (ashwagandha, rhodiola) and lifestyle optimization before considering hormone replacement.

Testosterone and DHEA: Both are commonly suppressed in CIRS. Once the biotoxin burden is reduced, testosterone and DHEA often normalize partially. Persistent deficiency after binder therapy warrants DHEA supplementation trial (25-50 mg/day) with monitoring.

VIP (Vasoactive Intestinal Polypeptide): VIP is a regulatory neuropeptide that normalizes inflammatory cytokines, improves pulmonary blood flow, and restores MSH. VIP nasal spray (Shoemaker Protocol Step 11) is used only after all prior steps are complete — using VIP before the environment is safe or before binders are working can worsen CIRS. VIP requires compounding pharmacy prescription.

Step 5: Targeted Nutritional Support

Several nutritional interventions address specific mechanisms of mycotoxin toxicity. Glutathione (liposomal, 500–1,000 mg/day) is the primary intracellular antioxidant involved in mycotoxin phase II conjugation — depletion of glutathione is a consistent finding in mold illness and impairs mycotoxin metabolism. N-acetylcysteine (NAC) (600 mg 2-3x/day) replenishes glutathione precursors and has direct antioxidant activity — it is the most practical and affordable glutathione support supplement. Phosphatidylcholine (4–8g/day) supports cellular membrane repair, which is damaged by trichothecenes. Vitamin D (optimize to 60–80 ng/mL) modulates TGF-beta-1 and supports innate immune function. Omega-3 EPA+DHA (3–4g/day) reduces TGF-beta-1 and MMP-9 driven neuroinflammation.

Mold Illness vs. Mold Allergy: The Diagnostic Distinction

The clinical presentation and testing approach differ fundamentally:

Mold allergy (IgE-mediated): Seasonal or exposure-triggered symptoms (sneezing, runny nose, itchy eyes, asthma exacerbation). Symptoms improve away from exposure. Positive skin prick test or specific IgE (RAST) to mold antigens (Alternaria, Aspergillus, Cladosporium, etc.). Treatable with antihistamines, nasal corticosteroids, and allergen immunotherapy. Not associated with the multi-system pattern of CIRS. Normal C4a, TGF-beta-1, MSH.

CIRS (biotoxin illness): Persistent multi-system symptoms across neurological, musculoskeletal, respiratory, GI, and hormonal domains. Symptoms may persist for months or years after leaving exposure source. Negative standard allergy testing. Abnormal VCS, elevated C4a and TGF-beta-1, low MSH. HLA-DR susceptibility genotype. Requires binder therapy, not antihistamines. Standard immunotherapy is ineffective and potentially harmful.

A patient can have both IgE-mediated mold allergy AND CIRS simultaneously, but they require different treatment approaches targeting different mechanisms.

The Gut Connection: Mold, Leaky Gut, and the Microbiome

Mycotoxin exposure and gut health create a bidirectional dysfunctional relationship. Trichothecenes, ochratoxin A, and aflatoxins all directly damage intestinal epithelial tight junctions, increasing intestinal permeability. This allows LPS (lipopolysaccharide from gram-negative bacteria) and undigested food particles to translocate into systemic circulation, amplifying the innate immune activation already present from mycotoxin recirculation. Mycotoxins also selectively suppress beneficial gut bacteria (Lactobacillus and Bifidobacterium species are particularly vulnerable to ochratoxin A and zearalenone) while sparing and even promoting pathogenic species.

This creates a vicious cycle: mold exposure damages the gut, gut dysbiosis amplifies inflammatory burden, increased intestinal permeability worsens mycotoxin reabsorption, and systemic inflammation further impairs detoxification capacity. Comprehensive gut restoration — using L-glutamine, zinc, fermented foods, and targeted probiotic supplementation — is an important adjunct to binder therapy in CIRS treatment.

Common Misdiagnoses and the Diagnostic Delay Problem

The average CIRS patient sees 3-7 physicians before receiving a correct diagnosis, with diagnostic delays of 2-10 years being common. The misdiagnoses most frequently given include: depression or anxiety (the cognitive and mood symptoms are real but secondary to neuroinflammation, not primary psychiatric disease), fibromyalgia (the widespread pain pattern is identical but has a biotoxin driver), chronic fatigue syndrome/ME-CFS (an overlapping condition that in some cases has mold as the triggering and perpetuating factor), somatization disorder or medically unexplained symptoms (when all standard tests are normal), Lyme disease or post-Lyme syndrome (Lyme and CIRS have overlapping symptoms and both produce abnormal C4a — differential requires specific testing for both), and thyroid disease (which is a real comorbidity in some CIRS patients but does not explain the full symptom picture).

The key diagnostic clue: multi-system symptoms involving cognition, fatigue, pain, respiratory, and mood simultaneously, in a patient with identifiable water-damaged building exposure, who has not responded to standard treatments for any of the individual diagnoses offered. This pattern warrants CIRS workup regardless of whether standard labs are normal.

The Bottom Line

Mold-related illness is one of the most underdiagnosed and undertreated conditions in functional medicine. CIRS affects an estimated 24% of the population genetically and is triggered by water-damaged building exposure in susceptible individuals. It is not an allergic condition — standard allergy testing misses it entirely. The correct diagnosis requires VCS testing, HLA-DR genotyping, and specific inflammatory biomarkers (C4a, TGF-beta-1, MSH). The treatment protocol is sequential and specific: remove from exposure → interrupt enterohepatic mycotoxin recirculation with binders → treat MARCoNS → correct downstream hormonal disruption → targeted nutritional support for detoxification capacity. Attempting to treat the individual symptoms (fatigue, brain fog, pain, mood) without addressing the biotoxin driver produces no lasting benefit.

If you have persistent multi-system symptoms with a history of water-damaged building exposure and have not found answers through conventional workups, a comprehensive CIRS evaluation is the appropriate next step. Call our office at (810) 206-1402 to discuss functional medicine assessment for biotoxin illness and chronic inflammatory conditions.

Frequently Asked Questions

How do you know if mold is making you sick?
The CIRS symptom pattern — multi-system symptoms including brain fog, fatigue, widespread pain, respiratory symptoms, and mood changes — in a person with water-damaged building exposure history, who has not responded to standard treatments, is the primary clinical indicator. VCS (Visual Contrast Sensitivity) testing is the best initial screening tool: positive VCS + symptom cluster + exposure history = high suspicion for CIRS. Confirmation requires the inflammatory biomarker panel (C4a, TGF-beta-1, MSH) and urine mycotoxin testing. Negative standard allergy testing does NOT rule out CIRS.

What is the best treatment for mold toxicity?
The validated treatment sequence is: (1) Remove from exposure — essential and non-negotiable; (2) Interrupt mycotoxin recirculation with cholestyramine (4g 4x/day) or natural binders (activated charcoal, bentonite clay, GI Detox+); (3) Treat MARCoNS nasal biofilm if present; (4) Correct downstream hormonal abnormalities (MSH, testosterone, cortisol axis); (5) Targeted nutritional support — glutathione/NAC, omega-3, vitamin D, phosphatidylcholine. The sequence matters — binders before MARCoNS treatment, environment remediated before VIP therapy.

Can mold exposure cause long-term health problems?
Yes, particularly in the 24% of the population with HLA-DR susceptibility. In these individuals, mycotoxins do not self-clear — they recirculate indefinitely through enterohepatic cycling, producing persistent innate immune activation. Without treatment, CIRS is associated with progressive neuroinflammation (measurable gray matter reduction on NeuroQuant MRI), chronic HPA axis dysregulation, gut microbiome destruction, and long-term immune dysfunction. Early identification and treatment significantly improves prognosis. Prolonged untreated CIRS produces more entrenched hormonal and immunological abnormalities that take longer to correct.

What foods should you avoid if you have mold illness?
Food mycotoxins compound the body burden from building exposure. The highest-risk foods are: corn and corn products (aflatoxins and fumonisins), peanuts and peanut butter (aflatoxin B1 — peanuts are grown underground in contact with soil fungi), coffee (ochratoxin A — present in a significant percentage of conventionally processed coffee; low-mycotoxin coffee from high-altitude single-origin producers is lower risk), alcohol (especially wine and beer — both contain ochratoxin A and other mycotoxins), dried fruits (aflatoxins, ochratoxin A), and wheat, barley, and oats (deoxynivalenol/DON from Fusarium). During active CIRS treatment, a low-mycotoxin diet — emphasizing fresh vegetables, pastured meats, wild-caught fish, and low-sugar fruit — reduces total mycotoxin load and supports recovery.

Mold Illness (CIRS): Testing, Symptoms, and the Shoemaker Treatment Protocol